Nidan, TTTav66 submitted some good DD on the WSU/BIIB connection previously and I made the comments below. IMHO the WSU presentation would not be made without agreement of all three parties. With that said, I think collaboration between ANAVEX and Biogen on the use of 2-73 for treatment of M/S, wether alone or in combo with Opicinumab, is still very much alive. What court (ANAVEX or Biogen's BOD) is unknown. But, what we do know is that WSU is presenting favorable information on 2-73's efficacy in M/S and the ANAVEX/Biogen MTA is still in effect.
-----
McM, The MTA for M/S seems to be discussed ad infinitum. The Sep 2016 PR announcing the MTA said this : " A satisfactory result from the OPC assay may lead to an in vivo remyelination study using a chemical demyelination model." Given that the MTA is still in progress and your info on the average length for an in vivo study, the testing and data analysis must be in the final stage or complete. Also given that the Biogen Laboratory would be considered one if not the most advanced facility for the testing of M/S drugs, IMHO ANAVEX/Biogen know the potential of 2-73 as a M/S treatment. Consequently, there is high probability that we are in the business negotiation stage currently. The Wayne State presentation given the current ANAVEX/Biogen/WSU lash-up is just academic underpinning for FDA submission.
From my previous post on the subject with the Biogen Lab video which points out the importance of REMYELINATION to the treatment of M/S.
Talon
-----
Re: TTTav66 post# 122777
Post # of 124936
TT, Great deep dive into due diligence, especially about Biogen's collaboration with WSU. I have mentioned in previous posts that the request for the MTA was probably initiated by Biogen based on problems with Opicinumab (Anti-Lingo), their primary remyelination drug and their knowledge of 2-73's remyelination success in the WSU study. This may add credence to that point. The upcoming presentation by WSU will also add to validation of the efficacy of the Sigma 1 platform in M/S. How much this was abetted by the in-house testing by Biogen's lab may soon be known.
The evidence that 2-73 may play a role in Biogen's core M/S program is mounting. At the risk being redundant, I will relink the Biogen Lab video, where Dr Sandrock and three other Drs expound on the crucial importance of remyelination to effective M/S treatment. ( Recently deleted)
